Head And Neck Squamous Cell Carcinoma, Upper Gastrointestinal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Metastatic Castration-Resistant Prostate Cancer
CHRSCoherus BioSciences Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Tagmokitug (CCR8 Antibody) in Head And Neck Squamous Cell Carcinoma, Upper Gastrointestinal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Metastatic Castration-Resistant Prostate Cancer. The expected timing is based on the latest available company guidance and may change.
03/09/26:- Multiple Ph1b/2a tagmokitug/toripalimab combos enrolling; first HNSCC and upper GI data expected Mid-2026. 05/11/26:- Mid-2026 HNSCC/upper GI data unchanged; ESCC, CRC data H2 2026; mCRPC pasritamig combo Ph1b starts fall 2026. 08/05/26:- Tagmokitug activity emerging; HNSCC, upper GI, ESCC, CRC data expected October 2026.
Verification
Confirm timing and program details against the company announcement or filing.